Teva Pharma (TEVA) Guides FY09, FY10 Inline With the Street
Teva Pharma (Nasdaq: TEVA) sees FY09 EPS of $3.30-$3.40, versus the consensus of $3.36, and FY10 EPS of $4.40-$4.60, versus the Street estimate of $4.48.
You May Also Be Interested In
- UPDATE: Auriga Starts Teva Pharma (TEVA) at Hold; Sidelined Until New CEO Is Convincing
- Xueda Education Group (XUE) Tops Q1 EPS by 6c; Guides Q2 Revs Above Views; Reaffirms FY12
- Pandora Media (P) Tops Q1 EPS by 8c; Offers Promising Q2, FY13 Outlook
Create E-mail Alert Related Categories
GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
